THE NHS is failing to keep up with science, experts blasted after breakthrough new dementia drugs were rejected again by the regulator. Charities and scientists said patients are being left behind ...

Two drugs to treat Alzheimer’s disease have been rejected for use on the NHS because their benefits are “too small” to justify their cost, the health spending watchdog has said. The National Institute ...

New immunotherapy drugs offer some hope in the fight against Alzheimer's disease but they're too pricey for the NHS ...

Donanemab patient: ‘The drug kept me feeling normal, but i’m scared about what happens next’ - Peter Almond finished a trial ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...

Drugs that slow progression of Alzheimer’s don’t provide enough benefit to justify substantial cost for NHS, regulator has said ...

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to suggest this could herald ...

Last week, it was announced that two new “breakthrough” treatments for Alzheimer’s had been turned down for NHS use. The tone ...

Donanemab works similarly to lecanemab, another promising Alzheimer's drug. Patients on lecanemab need infusions every two weeks, while donanemab is administered once a month.

It would help the trials—and patients—if more people were tested for Alzheimer’s earlier on, so that they could be enrolled to try the new drugs. A single register of those with the disease would also ...

Lilly continues to study donanemab in multiple clinical trials, including TRAILBLAZER-ALZ 3, focused on reducing risk of progression to symptomatic AD in participants with preclinical Alzheimer's ...

Two breakthrough Alzheimer's drugs have been deemed far too expensive, for too little benefit, to be offered on the NHS. The ...